The CHS advocates for access to a secure supply of the safest and most efficacious therapies for the treatment of inherited bleeding disorders.
Click here to access the Safe, secure blood supply – Report cards
Submissions on the funding of extended half‐life factor concentrates
Eloctate™ and Alprolix™, extended half-life factor VIII and factor IX for the treatment of hemophilia A and B, are approved by Health Canada. The Canadian Hemophilia Society submitted its recommendations concerning reimbursement in 2014. In 2016, both Canadian Blood Services and Héma-Québec added the two products to the list of those that could be reimbursed through their blood system budgets.